United Arab Emirates Drug Delivery Devices Market Size

UAE Drug Delivery Devices Market Analysis

The UAE drug delivery devices market is poised to register a CAGR of 20% over the forecast period.

COVID-19 has significantly impacted the growth of drug delivery devices in the United Arab Emirates. Due to the increased infection among the population, the demand for vaccines has increased, which has fueled the demand for drug-delivery devices in the country. For instance, from an article published in Nature Immunology in July 2021, it has been observed that in cooperation with international organizations, the Abu Dhabi Medical Devices Company delivered more than 500 million syringes and needles for COVID-19 vaccinations, which was equal to 25% of UNICEF and COVAX's projected global need for 2021. Moreover, with the released COVID-19 restrictions, resumed services and treatment procedures as well as increased patient visits, the demand for drug delivery devices for administering drugs is expected to increase over the forecast period. This, in turn, is anticipated to fuel market growth.

Certain factors that are propelling the market growth are the increased prevalence of chronic diseases, technological advancements, rising individual therapy, the growing understanding of drug metabolism among the population, and the requirement for controlled drug release.

As drug delivery devices help deliver drugs, which are beneficial for the targeted population to recover faster, there has been a growing adoption and inclination toward advanced drug delivery devices. Moreover, the increasing number of cancers, respiratory diseases, and diabetic patients across the world may promote the adoption of drug-delivery devices and drive the overall market. For instance, as per the GLOBOCAN 2020 factsheet, 4,807 new cancer cases were reported in 2020 in the United Arab Emirates, while the five-year prevalence (all ages) was 14,816. In addition, as per the same source, 1,030 new cases of breast cancer, 405 of thyroid cancer, 334 colon cancer, 270 prostate cancer, 226 lung cancer, and 164 rectum cancer were reported in 2020 in the United Arab Emirates. Also, the highest prevalence of cancer was found in women (2,652) compared to men (2,155). This growing burden of cancer increases the adoption of drug-delivery devices, which is expected to contribute significantly to market growth over the forecast period.

In addition, according to the 2022 statistics published by the IDF, in the United Arab Emirates, 0.99 million people were living with diabetes in 2021. In addition, as per the same source, this number is projected to reach 1.17 million by 2030 and 1.32 million by 2045. Thus, the increase in the number of people suffering from diabetes is expected to fuel the demand for novel drug delivery devices, which, in turn, is anticipated to propel market growth over the forecast period.

Similarly, according to an article published in the World Journal of Gastroenterology in July 2020, about 372,000 people were projected to develop the non-alcoholic fatty liver disease (NAFLD) in the United Arab Emirates by 2030. In addition, as per the same source, the prevalence of NAFLD was expected to rise by 87% by 2030 in the United Arab Emirates. Thus, the increase in the population suffering from NAFLD is expected to increase the demand for nanocarrier drug delivery system that delivers the drug to specific liver cell types that help in improving efficacy and reducing side effects. This is anticipated to fuel the growth of drug delivery devices in the country over the forecast period.

Furthermore, as per a meta-analysis study published in December 2021, it has been observed that the combined prevalence of hypertension was 31% in the United Arab Emirates. In addition, as per the same source, the prevalence of hypertension was highest in Dubai (37%) than in the Abu Dhabi region (29%). Thus, the elevated blood pressure in the population causes the left ventricle to thicken, which increases the risk of heart attack, and cardiac failure. This is expected to increase the demand for conventional and advanced drug delivery devices, thereby propelling market growth.

However, the risk of needlestick injuries is likely to hinder the market growth over the forecast period.